The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.
Related Keywords
, Emerging Therapies , Breast Cancer , Metastatic Breast Cancer , Mbc , Abc , Breast Cancer Treatments , Breast Cancer Therapies , Metastatic Breast Cancer Treatments ,
comparemela.com © 2020. All Rights Reserved.